Advertisement

Medication Efficacy and Side Effects in Older Asthmatics

  • Pinkus Goldberg
Chapter

Abstract

The older adult asthmatic population is increasing, as is the complexity of asthma treatments. This segment of asthmatics has been understudied, and modalities of therapy are affected by the aging process and comorbid diseases. Corticosteroids are the mainstay of emergency care and of chronic persistent asthma care. Inhaled bronchodilators have proven effective both in the acute setting and as an add-on therapy for chronic control. Leukotriene inhibitors have value especially where inhaler techniques are problematic. Theophylline has bronchodilator and potentially anti-inflammatory effects but requires close monitoring of drug levels. Specific allergen immunotherapy using both subcutaneous and sublingual routes of administration may have value in disease modification but requires further evaluation in the older adult. Biological therapies are available for severe asthma but require further controlled studies in older adults. Complementary medical methodologies are commonly used by patients but not adequately evaluated for efficacy or safety in older adults. Vaccines and good adherence measures are essential due to the polypharmacy and comorbidities inherent to an older adult population.

Keywords

Asthma Older adults Treatments Individualized medications Side effects 

Notes

Acknowledgments

Rebecca A Goldberg RN, BS Acct., Barbara A. Gushrowski, MLS, Manager of Library Services at Community Health Network, Indianapolis, Indiana.

Potential Conflicts of Interest

Consultant and or Speaker for AstraZeneca, Genentech, Boehringer Ingelheim, Circassia, Shire.

References

  1. 1.
    Battaglia S, Benfante A, Scichilone N. Asthma in the older adult: presentation, considerations and clinical management. Expert Rev Clin Immunol. 2015;11(12):1297–308.PubMedCrossRefGoogle Scholar
  2. 2.
    Battaglia S, et al. Are asthmatics enrolled in randomized trials representative of real-life outpatients? Respiration. 2015;89(5):383–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Dunn RM, Busse PJ, Wechsler ME. Asthma in the elderly and late-onset adult asthma. Allergy. 2018;73(2):284–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Bellanti JA, Settipane RA. Atopy, asthma, and the elderly: a paradigm for personalized therapy. Allergy Asthma Proc. 2017;38(3):167–9.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Godinho Netto AC, et al. Fraction of exhaled nitric oxide measurements in the diagnoses of asthma in elderly patients. Clin Interv Aging. 2016;11:623–9.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Scichilone N, et al. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clin Mol Allergy. 2015;13(1):7.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Horak F, et al. Diagnosis and management of asthma – statement on the 2015 GINA guidelines. Wien Klin Wochenschr. 2016;128(15–16):541–54.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Spaggiari L, et al. Exacerbations of severe asthma: a focus on steroid therapy. Acta Biomed. 2014;85(3):205–15.PubMedGoogle Scholar
  9. 9.
    Lefebvre P, et al. Burden of systemic glucocorticoid-related complications in severe asthma. Curr Med Res Opin. 2017;33(1):57–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Baptist AP, Busse PJ. Asthma over the age of 65: all’s well that ends well. J Allergy Clin Immunol Pract. 2018;6(3):764–73.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Kim MY, Song WJ, Cho SH. Pharmacotherapy in the management of asthma in the elderly: a review of clinical studies. Asia Pac Allergy. 2016;6(1):3–15.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(4):580–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Busse PJ, et al. Effect of aging on sputum inflammation and asthma control. J Allergy Clin Immunol. 2017;139(6):1808–1818 e6.PubMedCrossRefGoogle Scholar
  14. 14.
    Slavin RG, et al. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol. 2006;96(3):406–14.CrossRefGoogle Scholar
  15. 15.
    Hartert TV, et al. Underutilization of controller and rescue medications among older adults with asthma requiring hospital care. J Am Geriatr Soc. 2000;48(6):651–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Dunn RM, et al. Impact of age and sex on response to asthma therapy. Am J Respir Crit Care Med. 2015;192(5):551–8.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Hira D, et al. Problems of elderly patients on inhalation therapy: difference in problem recognition between patients and medical professionals. Allergol Int. 2016;65(4):444–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Melani AS, et al. Time required to rectify inhaler errors among experienced subjects with faulty technique. Respir Care. 2017;62(4):409–14.CrossRefGoogle Scholar
  19. 19.
    Ishiura Y, et al. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in elderly asthmatics. Drug Res (Stuttg). 2018;68(1):38–44.CrossRefGoogle Scholar
  20. 20.
    Turan O, Turan PA, Mirici A. Parameters affecting inhalation therapy adherence in elderly patients with chronic obstructive lung disease and asthma. Geriatr Gerontol Int. 2017;17(6):999–1005.PubMedCrossRefGoogle Scholar
  21. 21.
    Hirose M, et al. Sex differences in use of inhalants by elderly patients with asthma. Clin Interv Aging. 2015;10:1305–10.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Serper M, et al. Health literacy, cognitive ability, and functional health status among older adults. Health Serv Res. 2014;49(4):1249–67.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Park HW, et al. Prediction of asthma exacerbations in elderly adults: results of a 1-year prospective study. J Am Geriatr Soc. 2013;61(9):1631–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhou W, Ke H, Li Y. Effect of nebulized corticosteroids on long-term poorly controlled asthma in elderly patients. Chin J Geriatr. 2015;34(7):711–4.Google Scholar
  25. 25.
    Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA. 1998;280(6):539–43.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Ernst P, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J. 2006;27(6):1168–74.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Leone FT, et al. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest. 2003;124(6):2329–40.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Kagohashi K, et al. Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma. Exp Ther Med. 2014;7(4):1005–9.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Gupta P, O’Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. Drugs Aging. 2008;25(5):415–43.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Bellia V, et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest. 2007;132(4):1175–82.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Connolly MJ. Ageing, late-onset asthma and the beta-adrenoceptor. Pharmacol Ther. 1993;60(3):389–404.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Connolly MJ, et al. Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest. 1995;108(2):401–6.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2014;1:CD003137.Google Scholar
  35. 35.
    O’Byrne PM, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest. 2008;134(6):1192–9.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Stanford RH, et al. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a medicare-eligible population. Am J Geriatr Pharmacother. 2012;10(6):343–51.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Cates CJ, et al. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2013;6:CD006924.Google Scholar
  38. 38.
    Cates CJ, et al. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2013;3:CD006922.Google Scholar
  39. 39.
    Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med. 2000;161(6):1862–8.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Sobieraj DM, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1473–84.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Slawson D. Long-acting muscarinic antagonists plus inhaled steroids is equal to long-acting beta-agonists plus inhaled steroids. Am Fam Physician. 2018;98(8).: OnlineGoogle Scholar
  42. 42.
    Kerstjens HA, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–207.PubMedCrossRefGoogle Scholar
  43. 43.
    Peters SP, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715–26.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Magnussen H, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008;102(1):50–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Tashkin DP, et al. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT(R) trial. Respir Res. 2015;16:65.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Korenblat PE, et al. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT). Ann Allergy Asthma Immunol. 2000;84(2):217–25.PubMedCrossRefGoogle Scholar
  47. 47.
    Creticos P, et al. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol. 2002;88(4):401–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Trinh HK, et al. Leukotriene receptor antagonists for the treatment of asthma in elderly patients. Drugs Aging. 2016;33(10):699–710.PubMedCrossRefGoogle Scholar
  49. 49.
    Ye YM, et al. Addition of montelukast to low-dose inhaled corticosteroid leads to fewer exacerbations in older patients than medium-dose inhaled corticosteroid monotherapy. Allergy Asthma Immunol Res. 2015;7(5):440–8.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Bozek A, et al. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma. 2012;49(5):530–4.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Columbo M. Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast. Asthma Res Pract. 2017;3:3.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Spears M, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J. 2009;33(5):1010–7.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188(8):901–6.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Ohta K, et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med. 2004;98(10):1016–24.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Verma P, Randhawa I, Klaustermeyer WB. Clinical efficacy of omalizumab in an elderly veteran population with severe asthma. Allergy Asthma Proc. 2011;32(5):346–50.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Garcia G, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144(2):411–9.PubMedCrossRefGoogle Scholar
  57. 57.
    de Llano LP, Vennera Mdel C, Alvarez FJ, Medina JF, Borderdas L, Pellicer C, Gonzalez H, Gullon JA, Martinez-Moragon E, Sabadell C, Zamarro S, Picado C. Effects of omalizumab in non-atopic asthma; results froma a Spanish multicenter registry. J Asthma. 2013;144:411–9.Google Scholar
  58. 58.
    Song WJ, et al. Staphylococcal enterotoxin sensitization in a community-based population: a potential role in adult-onset asthma. Clin Exp Allergy. 2014;44(4):553–62.PubMedCrossRefGoogle Scholar
  59. 59.
    Song WJ, et al. Staphylococcal enterotoxin IgE sensitization in late-onset severe eosinophilic asthma in the elderly. Clin Exp Allergy. 2016;46(3):411–21.PubMedCrossRefGoogle Scholar
  60. 60.
    Bachert C, Gevaert P, van Cauwenberge P. Staphylococcus aureus enterotoxins: a key in airway disease? Allergy. 2002;57(6):480–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Tversky JR, et al. Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon-alpha via Toll-like receptor 9. Clin Exp Allergy. 2008;38(5):781–8.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Maykut RJ, Kianifard F, Geba GP. Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis. J Asthma. 2008;45(3):173–81.PubMedCrossRefGoogle Scholar
  63. 63.
    Yalcin AD, et al. Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up. Clin Lab. 2014;60(9):1561–4.PubMedGoogle Scholar
  64. 64.
    de Roos EW, et al. Targeted therapy for older patients with uncontrolled severe asthma: current and future prospects. Drugs Aging. 2016;33(9):619–28.CrossRefGoogle Scholar
  65. 65.
    Bernstein DI, Mansfield L, Zangrilli J, Garin M. Efficacy of reslizumab in older patients (> 65 years) with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials. J Allergy Clin Immunol. 2016;137(2):AB86.CrossRefGoogle Scholar
  66. 66.
    Brusselle GG, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Brusselle G, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinohils. Pulm Pharmacol Ther. 2017;43:39–45.CrossRefGoogle Scholar
  68. 68.
    Wenzel S, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Dupixent (dupilumb) injection 200 mg. 300mg Full Prescribing, S. Genzyme, editor; 2018.Google Scholar
  70. 70.
    Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–76.PubMedCrossRefGoogle Scholar
  71. 71.
    Cox L, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter. J Allergy Clin Immunol. 2011;127(1)(3rd update): 51–55.Google Scholar
  72. 72.
    Lang DM. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy? Curr Allergy Asthma Rep. 2008;8(1):37–44.PubMedCrossRefGoogle Scholar
  73. 73.
    Marogna M, et al. Sublingual immunotherapy for allergic respiratory disease in elderly patients: a retrospective study. Eur Ann Allergy Clin Immunol. 2008;40(1):22–9.PubMedGoogle Scholar
  74. 74.
    Bozek A, et al. Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis. Am J Rhinol Allergy. 2014;28(5):423–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Canonica GW, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Emminger W, et al. The SQ house dust mite SLIT-Tablet is well tolerated in patients with house dust mite respiratory allergic disease. Int Arch Allergy Immunol. 2017;174(1):35–44.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Albert RK, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Kew KM, et al. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015;9:CD002997.Google Scholar
  79. 79.
    Simpson JL, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–55.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Cameron EJ, Chaudhuri R, Mair F, McSharry C, Greenlaw N, Weir CJ, et al. Randomized controlled trial of azithomycin in smokers with asthma. Eur Respir J. 2013;42(5):1412–5.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Burn J, et al. Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics. J Asthma. 2017;54(8):872–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Torrego A, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014;3:CD009910.Google Scholar
  83. 83.
    Wechsler ME, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med. 2011;365(2):119–26.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Nielsen NH, et al. Chronic asthma and chiropractic spinal manipulation: a randomized clinical trial. Clin Exp Allergy. 1995;25(1):80–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Balon J, et al. A comparison of active and simulated chiropractic manipulation as adjunctive treatment for childhood asthma. N Engl J Med. 1998;339(15):1013–20.PubMedCrossRefGoogle Scholar
  86. 86.
    Huntley A, White AR, Ernst E. Relaxation therapies for asthma: a systematic review. Thorax. 2002;57(2):127–31.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Hackman RM, Stern JS, Gershwin ME. Hypnosis and asthma: a critical review. J Asthma. 2000;37(1):1–15.PubMedCrossRefGoogle Scholar
  88. 88.
    Reilly D, et al. Is evidence for homoeopathy reproducible? Lancet. 1994;344(8937):1601–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Lewith GT, et al. Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial. BMJ. 2002;324(7336):520.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Bielory L. Adverse reactions to complementary and alternative medicine: ragweed’s cousin, the coneflower (echinacea), is “a problem more than a sneeze”. Ann Allergy Asthma Immunol. 2002;88(1):7–9.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Vliagoftis H, et al. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Allergy Asthma Immunol. 2008;101(6):570–9.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Pinkus Goldberg
    • 1
    • 2
    • 3
  1. 1.Indiana University School of MedicineIndianapolisUSA
  2. 2.Internal MedicineCommunity Hospitals Health Care System of IndianaIndianapolisUSA
  3. 3.Allergy Partners of Central IndianaIndianapolisUSA

Personalised recommendations